In vitro validation of the amoebicidal activity of commercial eye drops as second activity

• Published in: International journal for parasitology -- drugs and drug resistance 2021-04, Vol.15, p.144-151
• Main Authors: Chiboub, Olfa, Capote-Yanes, Eulalia, Sifaoui, Ines, Reyes -Batlle, María, Rodríguez - Expósito, Rubén L., Piñero, José E., Lorenzo-Morales, Jacob
• Format: Article
• Language: English
• Subjects: Acanthamoeba - drug effects; Acanthamoeba spp; Amebicides - pharmacology; Amebicides - therapeutic use; Amoebicidal activity; Eye-drop; Ophthalmic Solutions - pharmacology; Ophthalmic Solutions - therapeutic use; PCD; Regular article; Trophozoites
• ISSN: 2211-3207; 2211-3207
• DOI: 10.1016/j.ijpddr.2021.02.007

The validation of anti-Acanthamoeba activity of commercial eye drops has gained a great interest recently and a growing number of commercials eye drop were evaluated for their aptitude to inhibit Acanthamoeba as a second pharmacological effect. In the present study, three different eye drops, commercializing in Spain, including TobraDex, Cusimolol and Colircusi antiedema have been tested in vitro against trophozoites and cysts stage of the facultative pathogen Acanthamoeba. The alamarBlue™ method was used to evaluate both trophocidal and cysticidal properties. The most active eye drops were tested for their impact on some programmed cell death features. We found out that the cells inhibition was strain and eye drop dependent, and 5% eye drop was able to eliminate both trophozoite and cyst stage of Acanthamoeba spp. A treatment of 24 h with 5% of TobraDex or Cusimolol was able to show DNA condensation, collapse in the mitochondrial membrane potential and reduction of the ATP level production in Acanthamoeba. We could assume that the present eye drops could induce programed cell death like process in Acanthamoeba via mitochondrial pathway. [Display omitted]